Showing 4961-4970 of 7244 results for "".
- Study: Excessive Sweating Linked to Sensitive Skinhttps://practicaldermatology.com/news/study-excessive-sweating-linked-sensitive-skin/2468351/A new study indicates a significant connection between primary hyperhidrosis, a condition of excessive sweating, and sensitive skin, where skin overreacts to stimuli like sweat and stress. The study was led by Practical Dermatology Editorial Board member Adam Friedman, MD, FAAD, chair of d
- Epicutis Launches Arctigenin Brightening Treatmenthttps://practicaldermatology.com/news/epicutis-launches-arctigenin-brightening-treatment/2468350/Epicutis announced that it has launched its Arctigenin Brightening Treatment, marking what the manufacturer called a significant shift in skin br
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in
- Kenvue to Present New Data Sets at EADV Congresshttps://practicaldermatology.com/news/kenvue-present-new-data-sets-eadv-congress/2468301/Kenvue announced the presentation of seven new data sets at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will feature Kenvue’s Aveeno and Neutrogena brands, “demonstrating the key to improved skin and hair outcome
- New Photoprotection Data at EADV Congresshttps://practicaldermatology.com/news/new-photoprotection-data-eadv-congress/2468300/Kenvue announced the presentation of two new data sets relating to photoprotection at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will demonstrate "the key to improved skin and hair outcomes through proactive use
- Roflumilast Cream Shows Consistent Results in AD Across Skin Typeshttps://practicaldermatology.com/news/roflumilast-cream-shows-consistent-results-ad-across-skin-types/2468298/Newly published pooled analyses of the INTEGUMENT trials suggest that ZORYVE (roflumilast) cream 0.15% showed significant improvements in atopic dermatitis (AD) symptoms, regardless of race, ethnicity, or Fitzpatrick skin type. Results from the studies showed that higher percentages of pat
- Aerolase Art of Diversity Conference Continues Growinghttps://practicaldermatology.com/news/aerolase-art-diversity-conference-continues-growing/2468263/Aerolase’s third annual Art of Diversity conference in Jersey City, New Jersey, lived up to its name, with a diverse mix of practitioners and content that led to an engaging educational program. “The whole idea of the Art of Diversity for Skin Health is that there is an eclectic community
- sNDA Accepted for Roflumilast Foam 0.3% for Psoriasishttps://practicaldermatology.com/news/snda-accepted-roflumilast-foam-03-psoriasis/2468261/The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for roflumilast foam 0.3%—a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor branded ZORYVE by Arcutis Biotherapeutics, Inc.—for the treatment of adults and adolescents ages 12 and ov